Assessing the effectiveness of methotrexate and actinomycin D in the treatment of patients with C-section ectopic pregnancy

Comparison of the effectiveness of methotrexate and actinomycin D in the treatment of patients with C-section ectopic pregnancy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151020024625N16

Enrollment

Registered

2023-04-04

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C-Section Ectopic Pregnancy. Ectopic pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Methotrexate is given as a single dose of 50 mg by intramuscular injection. This dose is repeated after 14 days if there is no therapeutic result. Intervention 2: I

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of -section ectopic pregnancy

Exclusion criteria

Exclusion criteria: Gestational age more than 13 weeks at the time of diagnosis Heavy vaginal bleeding Hemodynamic changes

Design outcomes

Primary

Measure	Time frame
Level of the blood chorionic gonadotropin hormone (BHCG). Timepoint: 4, 7, 14 and 21 days after intervention. Method of measurement: Enzyme-Linked Immunesorbent Assay (ELIZA).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Setareh Nasiri Zeidi

Iran University of Medical Sciences

setare_n99@yahoo.com+98 21 6435 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026